Hair loss can be traumatic and, unfortunately, extremely common. But a New Jersey doctor says he has a new treatment.

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.

An important unanswered question is whether rechallenging patients with enfortumab vedotin plus pembrolizumab after prior ICI exposure remains effective. The authors hypothesized that enfortumab ...

Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment. Dr. Saylani highlighted that Lutetium-177 vipivotide tetraxetan ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

When you’re low, you may experience adverse symptoms like a headache, dehydration, or mental confusion. Here’s how to tell if ...

KYZATREX is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX is safe or effective in males younger than 18 years old. Improper use may affect bone growth in ...

Another mother of a former clinic patient said she learned of the change on Wednesday when the parent of a child receiving ...

A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be ...

Nearly 7 million adults 65 or older in the U.S. are living with Alzheimer’s disease, with about 60% of those patients being women. Women are also more likely to have other dementias, according to the ...

Before referral to the clinic, the patient had been treated with testosterone therapy for 4 months for hypogonadism. This treatment had caused his initially low sperm concentration to fall to ...